Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Omeprazole on Taletrectinib PK in Healthy Chinese Males
NCT05609929Phase 1Completed
- Sponsor
- Nuvation Bio
- Start
- Nov 2022
- Primary completion
- Jan 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of taletrectinib in non-small cell lung cancer (NSCLC), sponsored by Nuvation Bio. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve to Last Measurable Concentration and 1 more. Started Nov 2022; status: completed.
02
Drugs
taletrectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05609929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05609929.